Booklet updates: Navigating your care

The following drug updates are listed by booklet title. This information is not found in the current version of these booklets, as these treatments were not FDA approved at the time the books were published.

Blood and Marrow Stem Cell Transplantation

Blood and Marrow Stem Cell Transplantation Guide

• In July 2026, the Food and Drug Administration (FDA) approved allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq (Tregzi™) for use in matched donor hematopoietic stem cell transplantation with myeloablative preparative regimen, for hematopoietic and immunologic reconstitution and to improve chronic graft-versus-host disease (cGVHD)-free survival, in the treatment of adults with hematological malignancies.
• In January 2026, the Food and Drug Administration (FDA) approved narsoplimab-wuug (Yartemlea®) for the treatment of adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (microangiopathy is a heart condition in which you might feel shortness of breath, chest pain or tightness, fatigue, and lack of energy, among other discomforts, due to the narrowing and poor functioning of the small cardiac arteries).
• In December 2024, the Food and Drug Administration (FDA) approved remestemcel-L-rknd (Ryoncil®) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months of age and older.
• In April 2023, the Food and Drug Administration (FDA) approved omidubicel-onlv (Omisirge®) for use in adults and pediatric patients 12 years and older with hematologic malignancies who are planned for umbilical cord blood transplantation following myeloablative conditioning to reduce the time to neutrophil recovery and the incidence of infection.

<< Previous Page